240 related articles for article (PubMed ID: 38475874)
1. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
2. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
Bloomfield-Clagett B; Rahman M; Smith K; Concato J
Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
[TBL] [Abstract][Full Text] [Related]
3. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
4. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
5. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
7. Use of Real-world Data for New Drug Applications and Line Extensions.
Bolislis WR; Fay M; Kühler TC
Clin Ther; 2020 May; 42(5):926-938. PubMed ID: 32340916
[TBL] [Abstract][Full Text] [Related]
8. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
Purpura CA; Garry EM; Honig N; Case A; Rassen JA
Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
[TBL] [Abstract][Full Text] [Related]
11. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
12. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
Lau C; Jamali F; Loebenberg R
J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
[TBL] [Abstract][Full Text] [Related]
14. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
Zisis K; Pavi E; Geitona M; Athanasakis K
J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
[No Abstract] [Full Text] [Related]
15. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
[TBL] [Abstract][Full Text] [Related]
17. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
Dagenais S; Russo L; Madsen A; Webster J; Becnel L
Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
[TBL] [Abstract][Full Text] [Related]
18. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
19. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
[TBL] [Abstract][Full Text] [Related]
20. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
